BioCentury
ARTICLE | Product Development

Independents’ day: after their first solo launch, biotechs look to new partnering strategies

How the next wave of independent companies are adapting for long term growth

May 3, 2019 11:29 PM UTC

Having taken their first products to market alone, the new class of independent biotechs face decisions for what to keep and what to change as they seek to build sustainable value as end-to-end companies. One model is to refine their BD strategy, but double down on their approach to physician and patient engagement.

An April analysis by BioCentury found a growing cohort of biotechs is breaking free of the traditional dependence on pharmas to get products over the finish line and onto the market...